Beta-blockers

Czech version

Authors: J. Ďuricová; M. Grundmann
Authors‘ workplace: Fakulta zdravotnických studií Ostravské univerzity, FN Ostrava, Ústav klinické farmakologie
Published in: Čes. slov. Farm., 2009; 58, 60-66
Category: Review Articles

Overview

Beta-adrenergic blockers rank among the principal drugs in the treatment of cardiovascular diseases. Their common mechanism of action is based on the ß-adrenergic receptor blockade. However, differences in pharmacokinetic and pharmacodynamic properties exist between the individual agents in the beta-blocker class, and these differences may be of clinical relevance. In addition, responses to beta-blockers are variable among patients. Genetic plymorphism in drug-metabolizing enzymes, including cytochrome P450 2D6, has been demonstrated to contribute to the variability of several beta-blockers. The understanding of beta-blocker properties and their differences is thus important for their proper clinical use.

Key words:
beta-blockers –⁠ pharmacokinetics –⁠ pharmacodynamics –⁠ P450 2D6

Sources

1. Reiter M. J.: Prog Cardiovasc Dis., 2004; 47, 11–33.

2. López–Sendón J., Swedberg K., McMurray J. et al.: Eur Heart J., 2004; 25, 1341–1362.

3. O’Rourke S. T.: Am J Pharm Educ., 2007; 71, 1–6.

4. Bristow M. R.: Circulation, 2000; 101, 558–569.

5. Vítovec J., Špinar J.: Interní Med., 2008; 10, 126–128.

6. Cruickshank J. M.: Circulation., 1990; 82, 60–65.

7. Andrus M. R., Loyed J. V.: Drugs Aging., 2008; 25, 131–144.

8. Prisant L. M.: J Clin Pharmacol., 2008; 48, 225–239.

9. Souček M.: Interní Med., 2008; 2, 58–61.

10. Keating G. M., Jarvis B.: Drugs, 2003; 63, 1697–1741.

11. McDevitt D. G.: Eur Heart J., 1987; 8, 9–14.

12. Riddell J. G., Harron D. W. G., Shanks R. G.: Clin Pharmacokinet., 1987; 12, 305–320.

14. Mehvar R., Brocks D. R.: J Pharm Pharm Sci., 2001; 4, 185–200.

15. Fox K., García M. A., Ardissino D. et al.: Eur Heart J., 2006; 27, 1341–1381.

16. Bassand J. P., Hamm C. H. W., Ardissino D. et al.: Eur Heart J., 2007; 28, 1598–1660.

17. Bělohlávek J, Aschermann M.: Cor Vasa, 2008; 50, 1S7–1S23.

18. Janoušek S.: Interv Akut Kardiol., 2004; 3, 189–191.

19. van de Werf F., Bax J., Betriu A. et al.: Eur Heart J., 2008; 29, 2909–2945.

20. Gourine A., Bondar S. I., Spyer K. M. et al.: Circ Res., 2008; 102, 633–636.

21. Špinar J., Hradec J., Meluzín J. et al.: Cor Vasa, 2007; 49, 5–34.

22. Prakash A., Markham A.: Drugs, 2000; 60, 647–678.

23. Dahlöf B., Sever P. S., Poulter N. R. et al.: Lancet, 2005; 366, 895–906.

24. Dahlöf B., Devereux R. B., Kjeldsen S. E. et al.: Lancet, 2002; 359, 1004–1010.

25. Grundmann M., Kacířová I.: Postgraduální medicína., 2007; 9, 652–660.

26. Widimský J., Cífková R., Špinar J. et al.: Cor Vasa., 2008; 50, 5–22.

27. Zipes D. P., Camm A. J., Borggrefe M. et al.: Europace., 2006; 8, 746–837.

28. Blomström–Lundqvist C, Sheinman MM, Aliot EM a kol. J Am Coll Cardiol., 2003; 42 : 1493–1531.

29. Anzenbacher P., Anzenbacherová E.: CMLS Cell Mol Life Sci., 2001; 58, 737–747.

30. Mičuda S., Martínková J., Chládek J. et al.: Remedia., 1998; 8, 226–236.

31. Bernard S., Neville K. A., Nguyen A. T. et al.: Clinical Implications. Oncologist., 2006; 11, 126–135.

32. Buzková H., Pechandová K., Slanař O. et al.: Prague Med Rep., 2006; 107, 383–393.

33. Volotinen M., Turpeinen M., Tolonen A. et al.: Drug Metab Dispos., 2007; 35, 1135–1141.

34. Lewis R. V., Lennard M. S., Jackson P. R. et al.: Br. J. Clin. Pharmacol., 1985; 19, 329–333.

35. Lennard M. S., Lewis R. V., Brawn L. A.: Br. J. Clin. Pharmacol., 1989; 27, 429–434.

36. Nieminen T., Uusitalo H., Mäenpää J. et al.: Eur. J. Clin. Pharmacol., 2005; 61, 811–819.

37. Zhou H. H., Wood A. J. J.: Clin. Pharmacol. Ther., 1995; 57, 518–524.

38. Ishida K., Taira S., Morishita H. et al.: Bil. Pharm. Bull., 2008; 31, 1297–1300.

39. Honda M., Nozawa T., Igarashi N. et al.: Biol. Pharm. Bull., 2005; 28, 1476–1479.

40. Takekuma Y., Takenaka T., Kiyokawa M. et al.: Biol. Pharm. Bull., 2007; 30, 537–542.

41. Graff D. W., Williamson K. M., Pieper J. A. et al.: J. Clin. Pharmacol., 2001; 41, 97–106.

42. Lefebvre J., Poirier L., Poirier P. et al.: Br. J. Clin. Pharmacol., 2006; 63, 575–582.

43. Beresford R., Heel R. C.: Drugs., 1986; 31, 6–28.

44. Frishman W. H., Tepper D., Lazar E. J. et al.: J. Clin. Pharmacol., 1990; 30, 686–692.

45. de Groot M. J., Ackland M. J., Horne V. A. et al.: J. Med. Chem., 1999; 42, 4062–4070.

46. Zateyshchikov D. A., Minushkina L. O., Brovkin A. N. et al.: Fund. Clin. Pharmacol., 2007; 21, 437–443.

47. RegĆrdh C. G., Johnsson G.: Clin. Pharmacokinet., 1980; 5, 557–569.

48. Peřinová I., Ďuricová J., Brozmanová H., Kacířová I., Grundmann M.: Čes. a slov. Farm., 2008; 57, 254–259.

49. Cerqueira P. M., Cesarino E. J., Mateus F. H. et al.: Chirality., 1999; 11, 591–597.

50. Ismail R., Teh L. K.: J Clin Pharm Ther., 2006; 31, 99–109.

51. Koytchev R., Alken R. G., Vlahov V. et al.: Eur J Clin Pharmacol., 1998; 54, 469–474.

42. Seeringer A., Brockmöller J., Bauer S. et al.: Eur J Clin Pharmacol., 2008; 64, 883–888.

52. Kirchheiner J., Heesch C., Bauer S. et al.: Clin Pharmacol Ther., 2004; 76, 302–312.

53. Goryachkina K., Burbello A., Boldueva S. et al.: Eur J Clin Pharmacol 2008; 64, 1163–1173.

54. Bijl M. J., Visser L. E., van Schaik R. H. N. et al.: Clin Pharmacol Ther., 2009; 85, 45–50.

55. Wuttke H., Rau T., Heide R. et al.: Clin Pharmacol Ther., 2002; 72, 429–437.

56. Fux R., Mörike K., Pröhmer A. M. T. et al.: Clin Pharmacol Ther., 2005; 78, 378–387.

57. Zineh I., Beitelshees A. L., Gaedigk A. et al.: Clin Pharmacol Ther., 2004; 76, 536–544.

Labels

Pharmacy Clinical pharmacology

On the terms pharmaceutical care, pharmacy care, and good pharmacy practice

Beneficial effects of rutin, quercitrin and quercetin on inflammatory bowel disease

Production of isoflavonoids in the Trifolium pratense L. suspension culture

HPLC study of temperature influence on some enantiomer separations of sulfoxides, determination of some enantiomers of sulfoxides in rat serum

Studies of local anesthetics Part: 187 Extraction of 1-methyl-2-piperidinoethylesters of alkoxyphenylcarbamic acids from human plasma by imprinted polymers and its comparison with classic solid phase extraction

Use radionuclide x-ray fluorescence analysis for determination of heavy metals content in dextrans in solid and liquid state

Article was published in

Czech and Slovak Pharmacy

2009 Issue 2

Popular this week